ARS Pharmaceuticals (SPRY) Stock Forecast, Price Target & Predictions
SPRY Stock Forecast
ARS Pharmaceuticals stock forecast is as follows: an average price target of $26.00 (represents a 132.35% upside from SPRY’s last price of $11.19) and a rating consensus of 'Buy', based on 5 wall street analysts offering a 1-year stock forecast.
SPRY Price Target
SPRY Analyst Ratings
Buy
ARS Pharmaceuticals Price Target by Analyst
Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
---|---|---|---|---|---|---|
Aug 19, 2024 | Josh Schimmer | Cantor Fitzgerald | $30.00 | $14.24 | 110.67% | 168.10% |
Aug 12, 2024 | Strong Buy | Raymond James | $22.00 | $10.85 | 102.76% | 96.60% |
Jul 25, 2024 | Ryan Deschner | Raymond James | $18.00 | $10.40 | 73.08% | 60.86% |
Mar 05, 2024 | Roanna Ruiz | Leerink Partners | $18.00 | $8.65 | 108.09% | 60.86% |
Dec 13, 2022 | Leerink Partners | $14.00 | $7.12 | 96.63% | 25.11% |
ARS Pharmaceuticals Price Target by Period
1M | 3M | 12M | |
---|---|---|---|
# Anlaysts | - | - | 4 |
Avg Price Target | - | - | $22.00 |
Last Closing Price | $11.19 | $11.19 | $11.19 |
Upside/Downside | -100.00% | -100.00% | 96.60% |
Analyst Ratings Upgrades/Downgrades
Date | Company | Previous Rating | New Rating | Rating Change |
---|---|---|---|---|
Oct 08, 2024 | Leerink Partners | Underperform | Underperform | Hold |
Oct 08, 2024 | Raymond James | Strong Buy | Strong Buy | Hold |
Sep 09, 2024 | Raymond James | Strong Buy | Strong Buy | Hold |
Sep 09, 2024 | Dawson James | Underperform | Underperform | Hold |
Aug 19, 2024 | Cantor Fitzgerald | Overweight | Initialise | |
Aug 12, 2024 | Raymond James | Outperform | Strong Buy | Upgrade |
Jul 25, 2024 | Raymond James | Outperform | Initialise | |
Mar 05, 2024 | Leerink Partners | Outperform | Upgrade | |
Feb 20, 2024 | William Blair | Market Perform | Outperform | Upgrade |
Sep 21, 2023 | William Blair | Outperform | Market Perform | Downgrade |
Sep 20, 2023 | JMP Securities | Market Outperform | Initialise | |
Jan 04, 2023 | William Blair | Outperform | Initialise | |
Dec 13, 2022 | SVB Leerink | Outperform | Initialise |
ARS Pharmaceuticals Financial Forecast
ARS Pharmaceuticals Revenue Forecast
Quarter
Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | - | - | - | - | - | - | - | - | - | - | - | - |
Avg Forecast | $85.29M | $112.09M | $74.07M | $41.90M | $30.92M | $27.90M | $17.85M | $17.03M | $5.57M | $575.00K | $1.00M | $1.00M |
High Forecast | $136.35M | $179.20M | $118.41M | $66.98M | $49.43M | $44.60M | $28.54M | $20.82M | $14.11M | $919.25K | $1.60M | $1.60M |
Low Forecast | $49.14M | $64.58M | $42.67M | $24.14M | $17.81M | $16.07M | $10.28M | $13.22M | $664.08K | $331.26K | $576.11K | $576.11K |
# Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 3 | 1 | 1 | 1 |
Surprise % | - | - | - | - | - | - | - | - | - | - | - | - |
Forecast
ARS Pharmaceuticals EBITDA Forecast
Quarter
Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
# Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 3 | 1 | 1 | 1 |
EBITDA | - | - | - | - | - | - | - | - | - | - | - | - |
Avg Forecast | $-34.56M | $-45.42M | $-30.01M | $-16.98M | $-12.53M | $-11.30M | $-7.23M | $-6.90M | $-2.26M | $-232.99K | $-405.19K | $-405.19K |
High Forecast | $-19.91M | $-26.17M | $-17.29M | $-9.78M | $-7.22M | $-6.51M | $-4.17M | $-5.36M | $-269.08K | $-134.22K | $-233.43K | $-233.43K |
Low Forecast | $-55.25M | $-72.61M | $-47.98M | $-27.14M | $-20.03M | $-18.07M | $-11.56M | $-8.44M | $-5.72M | $-372.47K | $-647.78K | $-647.78K |
Surprise % | - | - | - | - | - | - | - | - | - | - | - | - |
Forecast
ARS Pharmaceuticals Net Income Forecast
Quarter
Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
# Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 3 | 1 | 1 | 1 |
Net Income | - | - | - | - | - | - | - | - | - | - | - | - |
Avg Forecast | $28.27M | $47.88M | $20.62M | $-5.40M | $-11.97M | $-21.02M | $-19.73M | $-16.82M | $-13.34M | $-13.83M | $-10.73M | $-9.60M |
High Forecast | $50.26M | $85.14M | $36.67M | $-2.43M | $-5.37M | $-9.44M | $-8.86M | $-11.77M | $38.54M | $-6.21M | $-4.82M | $-4.31M |
Low Forecast | $12.69M | $21.49M | $9.26M | $-9.61M | $-21.28M | $-37.39M | $-35.08M | $-21.86M | $-40.03M | $-24.59M | $-19.09M | $-17.07M |
Surprise % | - | - | - | - | - | - | - | - | - | - | - | - |
Forecast
ARS Pharmaceuticals SG&A Forecast
Quarter
Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
# Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 3 | 1 | 1 | 1 |
SG&A | - | - | - | - | - | - | - | - | - | - | - | - |
Avg Forecast | $27.16B | $35.70B | $23.59B | $13.34B | $9.85B | $8.88B | $5.68B | $5.42B | $1.77B | $183.11M | $318.45M | $318.45M |
High Forecast | $43.42B | $57.07B | $37.71B | $21.33B | $15.74B | $14.20B | $9.09B | $6.63B | $4.49B | $292.73M | $509.10M | $509.10M |
Low Forecast | $15.65B | $20.56B | $13.59B | $7.69B | $5.67B | $5.12B | $3.28B | $4.21B | $211.47M | $105.49M | $183.46M | $183.46M |
Surprise % | - | - | - | - | - | - | - | - | - | - | - | - |
Forecast
ARS Pharmaceuticals EPS Forecast
Quarter
Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
# Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 3 | 1 | 1 | 1 |
EPS | - | - | - | - | - | - | - | - | - | - | - | - |
Avg Forecast | $0.29 | $0.49 | $0.21 | $-0.06 | $-0.12 | $-0.22 | $-0.20 | $-0.17 | $-0.14 | $-0.14 | $-0.11 | $-0.10 |
High Forecast | $0.52 | $0.88 | $0.38 | $-0.03 | $-0.06 | $-0.10 | $-0.09 | $-0.12 | $0.40 | $-0.06 | $-0.05 | $-0.04 |
Low Forecast | $0.13 | $0.22 | $0.10 | $-0.10 | $-0.22 | $-0.39 | $-0.36 | $-0.23 | $-0.41 | $-0.25 | $-0.20 | $-0.18 |
Surprise % | - | - | - | - | - | - | - | - | - | - | - | - |
Forecast
ARS Pharmaceuticals Peer Comparison by Price Target
Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
---|---|---|---|---|---|
HEPA | Hepion Pharmaceuticals | $0.64 | $70.00 | 10837.50% | Buy |
INAB | IN8bio | $0.29 | $14.00 | 4727.59% | Buy |
DRMA | Dermata Therapeutics | $1.43 | $6.00 | 319.58% | Buy |
CNSP | CNS Pharmaceuticals | $0.12 | $0.50 | 316.67% | |
TCRX | TScan Therapeutics | $3.07 | $12.00 | 290.88% | Buy |
ZURA | Zura Bio | $2.58 | $10.00 | 287.60% | Buy |
IMMX | Immix Biopharma | $2.35 | $7.00 | 197.87% | Buy |
ANNX | Annexon | $5.41 | $14.00 | 158.78% | Buy |
SPRY | ARS Pharmaceuticals | $11.19 | $26.00 | 132.35% | Buy |
CUE | Cue Biopharma | $1.39 | $3.00 | 115.83% | Buy |
WVE | Wave Life Sciences | $13.51 | $22.14 | 63.88% | Buy |
PALI | Palisade Bio | $1.90 | $1.50 | -21.05% | Buy |
SPRY Forecast FAQ
Try Tickergate Pro Free
Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)
Customize your own personal stocks lists, views and charts
Choose from hundreds of fields, up to 15 years of history
Conduct deep comparison analysis
Discover trending investment themes
Find your next best investment
Research stocks using tools